Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $15.52 in the prior trading day, Takeda Pharmaceutical Co ADR (NYSE: TAK) closed at $15.07, down -2.90%. In other words, the price has decreased by -$2.90 from its previous closing price. On the day, 2.81 million shares were traded. TAK stock price reached its highest trading level at $15.32 during the session, while it also had its lowest trading level at $15.07.
Ratios:
Our goal is to gain a better understanding of TAK by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.43 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.71. For the most recent quarter (mrq), Quick Ratio is recorded 0.59 and its Current Ratio is at 1.16. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.60.
On March 16, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $20. Cowen Upgraded its Market Perform to Outperform on July 19, 2022, whereas the target price for the stock was revised from $21 to $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 09 ’25 when Thomas Wozniewski bought 6,136 shares for $15.42 per share.
Teresa Marie Bitetti bought 52,649 shares of TAK for $811,848 on Jul 09 ’25. On Jul 09 ’25, another insider, Ramona A Sequeira, who serves as the President, Global Portfolio Di of the company, bought 102,972 shares for $15.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TAK now has a Market Capitalization of 47594373120 and an Enterprise Value of 4715558993920. As of this moment, Takeda’s Price-to-Earnings (P/E) ratio for their current fiscal year is 50.96, and their Forward P/E ratio for the next fiscal year is 23.35. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.57 while its Price-to-Book (P/B) ratio in mrq is 0.99. Its current Enterprise Value per Revenue stands at 1.053 whereas that against EBITDA is 3.868.
Stock Price History:
The Beta on a monthly basis for TAK is 0.26, which has changed by 0.007352948 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, TAK has reached a high of $15.56, while it has fallen to a 52-week low of $12.80. The 50-Day Moving Average of the stock is 1.87%, while the 200-Day Moving Average is calculated to be 5.47%.
Shares Statistics:
The stock has traded on average 3.41M shares per day over the past 3-months and 3240940 shares per day over the last 10 days, according to various share statistics. A total of 3.12B shares are outstanding, with a floating share count of 3.12B. Insiders hold about 0.00% of the company’s shares, while institutions hold 2.51% stake in the company. Shares short for TAK as of 1753920000 were 8223830 with a Short Ratio of 2.41, compared to 1751241600 on 5087639. Therefore, it implies a Short% of Shares Outstanding of 8223830 and a Short% of Float of 0.26.
Dividends & Splits
In the trailing 12 months, TAK’s forward annual dividend rate was 196.0, compared to 0.33 this year. Against a Trailing Annual Dividend Yield of 12.628865The stock’s 5-year Average Dividend Yield is 4.69.
Earnings Estimates
Analysts are recommending an EPS of between $249.41 and $66.25 for the fiscal current year, implying an average EPS of $129.91. EPS for the following year is $161.99, with 3.0 analysts recommending between $273.16 and $90.47.
Revenue Estimates
5 analysts predict $1.17T in revenue for the current quarter. It ranges from a high estimate of $1.21T to a low estimate of $1.13T. As of the current estimate, Takeda Pharmaceutical Co ADR’s year-ago sales were $1.18TFor the next quarter, 5 analysts are estimating revenue of $1.18T. There is a high estimate of $1.25T for the next quarter, whereas the lowest estimate is $1.14T.
A total of 15 analysts have provided revenue estimates for TAK’s current fiscal year. The highest revenue estimate was $4.68T, while the lowest revenue estimate was $4.37T, resulting in an average revenue estimate of $4.55T. In the same quarter a year ago, actual revenue was $580.36BBased on 15 analysts’ estimates, the company’s revenue will be $4.58T in the next fiscal year. The high estimate is $4.73T and the low estimate is $4.38T.
